We designed a fluorescent peptide -magnetic nanoparticle conjugate that images E-selectin expression in mouse xenograft models of Lewis lung carcinoma (LLC) by fluorescence reflectance imaging. It was synthesized by attaching the E-selectin -binding peptide (ESBP; CDSDSDITWDQLWDLMK) to a CLIO(Cy5.5) nanoparticle to yield ESBP-CLIO(Cy5.5). Internalization by activated human umbilical vein endothelial cells (HUVECs) was rapid and mediated by E-selectin, indicated by the lack of uptake of nanoparticles bearing similar numbers of a scrambled peptide (Scram). To demonstrate the specificity of E-selectin targeting to ESBP-CLIO(Cy5.5) in vivo, we coinjected ESBP-CLIO (Cy5.5) and Scram-CLIO(Cy3.5) and demonstrated a high Cy5.5/Cy3.5 fluorescence ratio using the LLC. Histology showed that ESBP-CLIO was associated with tumor cells as well as endothelial cells, but fluorescenceactivated cell sorter analysis showed a far less expression of E-selectin on LLC than on HUVECs. Using immunohistochemistry, we demonstrated E-selectin expression in both endothelial cells and cancer cells in human prostate cancer specimens. We conclude that ESBP-CLIO (Cy5.5) is a useful probe for imaging E-selectin associated with the LLC tumor, and that E-selectin is expressed not only on endothelial cells but also on LLC cells and human prostate cancer specimens. Neoplasia (2005) 7, 904-911
Introduction
Selectins (E-, P-, and L-selectin) are a family of cell surface glycoproteins that mediate interactions between leukocytes and endothelial cells [1] . E-selectin is a C-type lectin of 97 kDa that binds to the tetrasaccharide sialyl Lewis X structure, which appears to be a minimal ligand involved in cell adhesion [2 -4] . E-selectin (CD62E and endothelial leukocyte adhesion molecule 1) is upregulated in endothelia by cytokines such as interleukin 1b (IL-1b) or tumor necrosis factor a, and is an early marker for the detection of inflammation [5, 6] . Although less established in inflammation and leukocyte migration, there is considerable evidence that an interaction between E-selectin and cancer cells may be involved in adhesion and metastases [7 -9] .
To develop a nanoparticle binding E-selectin, we conjugated peptides containing the DITWDQLWDLMK E-selectin -binding sequence to amino -CLIO(Cy5.5), a crosslinked dextrancoated iron oxide nanoparticle that is widely used for the attachment of biomolecules for in vitro and in vivo applications [10] [11] [12] . Peptides containing this sequence, termed E-selectinbinding peptides (ESBPs), bind E-selectin (but not P-selectin or L-selectin) noncompetitively with sialyl Lewis X with a dissociation constant of 3 to 5 nM and have a similar affinity for mouse or human E-selectins [13, 14] . Mouse and human E-selectins have a 73% sequence homology and many common immunologic determinants [15] . Probes using this sequence lack species specificity and can be used to target E-selectin in a wide variety of animal models and, potentially, clinically. In contrast, nanoparticles using a monoclonal antibody bind human E-selectin, but not mouse E-selectin [16, 17] , which prevents them from being used in animal models like the Lewis lung carcinoma (LLC) model used here.
We used the fluorescence of the ESBP -CLIO(Cy5.5) nanoparticle to monitor its interaction with LLC cells in vitro and by fluorescence reflectance imaging in vivo. With the LLC, fluorescence microscopy indicated that ESBP -CLIO(Cy5.5) was not associated with endothelial cells, as might be expected based on the function of E-selectin, but was present in both tumor and endothelial cells. We next examined histochemically the expression of E-selectin on human prostate cancer specimens and demonstrated that it was a frequently expressed marker. We conclude that the ESBP -CLIO( Cy5.5) nanoparticle can be used for imaging E-selectin expression by fluorescence reflectance and that E-selectin is expressed on both tumor and endothelial cells.
Methods
Peptides were synthesized by an Apex 396 peptide synthesizer using a standard solid-phase Fmoc chemistry (Advanced Chemtech, Lousiville, KY) and were purified by reverse-phase high-performance liquid chromatography, as described [12, 18] . The peptides used were (FITC)BCDSDS-DITWDQLWDLMKNH2 (ESBP) and (FITC)BCDSDSK-MIDWTWLQLDD-NH2 (scrambled peptide or Scram). ''B'' stands for b-alanine. The identity and purity of peptides were confirmed by mass spectroscopy. The amino -CLIO nanoparticle (crosslinked iron oxide) was synthesized as described and iron-assayed spectrophotometrically [11, 12] .
The linker chemistry for the E-selectin conjugating peptides to magneto-optical nanoparticles has been described in detail (see Figure 1 of Ref. [18] ). A fluorochrome (Cy3.5 or Cy5.5; Amersham Biosciences Corp., Piscataway, NJ) was first attached directly to the crosslinked dextran coating of the amino -CLIO nanoparticle, consuming one to two of the available 40 to 60 amino groups per nanoparticle and leaving many groups for further modification (e.g., attaching a subsequent peptide to the nanoparticle) [18, 19] .
To synthesize E-selectin -binding peptide -nanoparticle conjugates, amino -CLIO nanoparticles [10 mg/ml Fe, 2 mg, in phosphate-buffered saline (PBS)] were placed in a tube, and approximately 500 mg of Cy3.5 or Cy5.5 was added. After 2 hours at room temperature, succinimidyl iodoacetic acid (SIA; 140 mM in 100 ml of DMSO) was added, and the mixture was allowed to stand for 1 hour. Unreacted dye and SIA were removed using P-10 spin columns equilibrated in 0.02 M citrate and 0.15 M NaCl (pH 8). The peptides in DMSO were added at a concentration of 0.5 mg peptide/mg Fe to yield nanoparticles with approximately 30 peptides per nanoparticle. The average amount of attached peptides was determined using the absorbance of fluorescein [12] . The average number of peptides per nanoparticle was calculated by assuming 8000 Fe/CLIO nanoparticle [20] .
Human umbilical vein endothelial cells (HUVECs; Clonetics, Baltimore, MD) were cultured in an endothelial growth medium (Clonetics). Cells were stimulated to upregulate E-selectin by an exposure to recombinant human IL-1b (Fisher Scientific, Fairlawn, NJ) at a final concentration of 2 ng/ml for 4 hours. LLC cells (ATCC, Manassas, VA) were cultured in Dulbecco's modified Eagle's medium, with 4 mM L-glutamine adjusted to contain 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% fetal bovine serum (all culture supplements were from Invitrogen Corp., Paisley, Scotland, UK).
Nanoparticles were incubated with HUVECs (stimulated or unstimulated) as above (8 mg/ml Fe, 8 hours). Cells were washed three times in PBS, detached with 0.1% Trypsin -EDTA (2 minutes at 37jC), suspended in a cell culture medium at 4jC, and centrifuged (900g for 5 minutes). Cells were resuspended in a cell culture medium and kept on ice, and flow cytometry was performed (FacsCalibur; Becton Dickinson, Franklin Lakes, NJ). Relative median fluorescence intensity (Cy5.5 channel) was obtained as a measure of nanoparticle accumulation.
To obtain the concentration and time dependence of the uptake of ESBP-CLIO(Cy5.5) by HUVECs ( Figure 1, C and D) , confluent layers of IL-1b -stimulated cells in 24-well plates were incubated with ESBP -CLIO(Cy5.5) in a complete cell culture medium for 8 hours at 37jC. The uptake was measured using an FITC hapten immunoassay for immunoreactive FITC attached to the nanoparticle. Briefly, cells were washed three times with PBS and lysed with PBS containing 0.1% bovine serum albumin (BSA), 0.1% Triton X-100, and 1 mM 
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8-anilino-1-naphthalenesulfonic acid (1 ml/well). The lysate was first reacted overnight at 4jC with an anti-FITC horseradish peroxidase conjugate (Molecular Probes, Eugene, OR) at 40 ng/ml, and the mixture was then transferred onto a 96-well plate (200 ml/well, MaxiSorp Nunc, eBioscience, San Diego, CA) coated with 12.5 ng/ml FITC-labeled BSA (Sigma-Aldrich, St. Louis, MO). The plates were then washed three times (PBS, 0.1% BSA, and 0.1% Triton X-100), and horseradish peroxidase activity was quantitated at 650 nm using 200 ml of 3,3V,5,5V tetramethylbenzidine dihydrochloride after a 30-minute incubation at room temperature. Lysate iron concentrations were calculated from a displacement immunoassay standard curve using nanoparticle standards in a lysis medium. The number of cells per well was determined by trypsinizing and counting cells in a hemocytometer. A more complete description of the assay has been provided [21] .
To study the specificity of ESBP-CLIO(Cy5.5) interactions to E-selectin ( Figure 2 ), HUVECs were grown on fibronectincoated coverslips. At 8 mg/ml Fe, ESBP -CLIO(Cy5.5) or Scram -CLIO(Cy3.5) was added to IL-1b -stimulated and unstimulated confluent cell layers for 4 hours. During the last hour, a phycoerythrin (PE)-labeled mouse antihuman E-selectin antibody (BD Pharmingen, San Jose, CA) at 5 mg/ml was added. Cells were then washed three times with PBS, fixed in 2% paraformaldehyde, and mounted. Fluorescence images were obtained using a confocal microscope (Axiovert 200, Plan-Neofluar 40Â; Zeiss, Jena, Germany) with laser excitations at 488 nm (FITC) and 543 nm (PE). Image acquisition and analysis were done using the LSM 5 PASCAL Software (Zeiss). For dual-wavelength flow cytometry, cells were detached and suspended as described above.
For dual-fluorochrome in vivo imaging ( Figure 3 ), animals were treated in compliance with institutional and legal requirements. Eight nude mice (nu/nu; Charles River Laboratories, Boston, MA) underwent an injection of 2 million LLC cells into the left and right paralumbar regions. After 10 to 14 days, tumors were between 8 and 14 mm in diameter. Animals were anesthetized with 1.5% isofluorane in oxygen and imaged preinjection and 2, 4, 8, and 24 hours postinjection of an intravenous solution with a mixture of approximately 2 to 4 mg Fe/kg ESBP -CLIO(Cy5.5) and 2 to 4 mg Fe/kg Scram -CLIO(Cy3.5), with a final adjustment in concentration to provide for injections of equal fluorescence from each probe. White light and Cy5.5 and Cy3.5 fluorescent images were obtained with a custom-built whole-body mouse optical imaging system described previously [22, 23] , which was capable of multichannel fluorescent imaging without a significant spectral overlap. Digital images (16 bit) were acquired. Fluorescence intensity was quantitated as a region of interest of constant size comprising 96 pixels at the center of the maximum intensity of the tumor and on adjacent nontumoral tissues. Tumor fluorescence was computed as the tumor-to-background ratio, which was the ratio of the average signal intensity of the tumor divided by the average signal intensity of normal tissues adjacent to the tumor, the boundaries of which were easily visible ( Figure 3A) . After the last time point, the animals were sacrificed with an injection of pentobarbital sodium (100 mg/kg, i.p.), and tissues were processed for histology.
For histology (Figure 4 ), tumors were excised, placed in a freezing medium (Fisher Scientific), and frozen on dry ice. Cryosections (8 mm in thickness) were obtained, air-dried, fixed with acetone, blocked with PBS containing 0.5% donkey serum and 2% BSA, and incubated with a rat antimouse E-selectin (BD Pharmingen) at 1:100 or a rat antimouse CD31 at 1:200 (Molecular Probes). A secondary antibody (donkey anti-rat Cy3; Molecular Probes) was applied at 1:500 for 1.5 hours. Nuclei were stained with Sytox green (Molecular Probes) diluted 1:100,000 in PBS for 5 minutes. Sections were imaged using a confocal fluorescence microscope (Axiovert 200; Zeiss). Liver, spleen, and kidney sections served as E-selectin -negative controls, and mouse ear sections from a diazolone-induced hypersensitivity reaction (courtesy of Dr. Rainer Kunstfeld, Cutaneous Biology Research Center, Charlestown, MA) served as positive controls (data not shown).
To examine the expression of E-selectin by LLC cells in culture ( Figure 5 ), cells were grown in Dulbecco's modified Eagle's medium with 4 mM L-glutamine, 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, and 10% fetal bovine serum. Confluent LLC layers were incubated with ESBP-CLIO(Cy5.5) or Scram-CLIO(Cy3.5) (8 mg/ml Fe, 8 hours) and 2 mg/ml rat anti-mouse E-selectin (BD Pharmingen) for 1 hour at 37jC. Cell detachment and flow cytometry were performed as described in Figure 3 .
To determine the expression of E-selectin in human prostate cancers (Figure 6 ), 72 samples from histologically confirmed prostate adenocarcinomas were obtained (Dr. M. Rubin, Department of Pathology, Harvard Medical School, Charlestown, MA). Indigenous avidin and biotin were blocked using the Vector avidin -biotin blocking kit (Vector Laboratories, Burlingame, CA), followed by incubation of the samples with either E-selectin -specific monoclonal antibody IgG ab8165 (Abcam, Inc., Cambridge, MA) or GFP-specific monoclonal antibody IgG (Alpha Diagnostic International, San Antonio, TX) as a negative control at 1 mg/ml. The antibody was detected by a biotinylated secondary goat antimouse IgG ab6788 (Abcam, Inc.), diluted 1:200 in PBS, and developed for 8 minutes using the Vectastain Elite ABC kit (Vector Laboratories). Counterstaining was performed in hematoxylin for 1 minute. The samples were rated as highly positive when >75% of the cells were positive, medium positive when 50% to 75% of the cells were positive, low positive when 25% to 50% of the cells were positive, and negative when less than 25% of the cells were positive.
Results
Peptide -nanoparticle conjugates were synthesized with either E-selectin binding (ESBP) or Scram and either Cy5.5 or Cy3.5 (as shown in Figure 1A ), and were tested for interactions with IL-b -stimulated and unstimulated HUVECs.
We next examined the concentration and time dependence of the uptake of ESBP -CLIO(Cy5.5) with IL-1b -stimulated HUVECs. The uptake of ESBP -CLIO(Cy5.5) was proportional to nanoparticle concentration (1 -30 mg/ml Fe) and time (0 -8 hours), as shown in Figure 1 , B and C. The rate of uptake of ESBP -CLIO(Cy5.5) was 3.47 pg/cell Fe per hour at 8 mg/ml Fe. Consistent with the observations of Martens et al. [14] , an N-terminal attachment was found to be essential for preserving the E-selectin -binding activity of DITWDQLWDLMK-based peptide -nanoparticle conjugates (data not shown).
The specificity of the interaction of ESBP -CLIO(Cy5.5) to E-selectin in vitro was further examined as shown in 
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was lower and was not stimulated by IL-1b. To further examine the specificity of the interaction of ESBP -CLIO(Cy5.5) to E-selectin, HUVECs were examined by the dual-wavelength flow cytometry ( Figure 2B ). Here the uptake of ESBP -CLIO(Cy5.5) -labeled Cy5.5 nanoparticles was compared with the binding of a PE-labeled anti-human E-selectin. As expected, IL-1b treatment increased E-selectin expression, and cells expressing E-selectin internalized ESBP -CLIO(Cy5.5). However, IL-1b treatment failed to increase the uptake of Scram -CLIO(Cy5.5). We next examined the specificity of the interaction of ESBP -CLIO(Cy5.5) to E-selectin in vivo, as shown in Figure 3 . A mouse xenograft model of LLC was used as a model of E-selectin -expressing tissue because it is a rapidly growing tumor and is an excellent source of small blood vessels, which express E-selectin [24] . We examined nanoparticle accumulation in LLC using dual-channel intravital fluorescence microscopy, as shown in Figure 4 . Figure 3 shows white light (A), Cy5.5 fluorescence (B), and Cy3.5 fluorescence (C) images for the LLC xenograft model at various time points after the coinjection of both probes. The accumulation of Cy3.5 fluorescence by LLC was similar to the background, whereas Cy5.5 fluorescence was markedly increased. The time course of the tumor fluorescence ratio is shown in Figure 3D . Cy5.5 fluorescence increased, slowly reaching a plateau at about 4 hours postinjection, whereas Cy3.5 fluorescence was unchanged or decreased slightly. Because Cy5.5 and Cy3.5 were both attached to nanoparticle probes that matched in size, linker chemistry, and composition of attached amino acids and differed only in peptide sequence, the increase in Cy5.5 fluorescence indicated that ESBP -CLIO(Cy5.5) specifically bound E-selectin in vivo. Our data suggest a plasma half-life of roughly 1 to 2 hours for ESBP -CLIO(Cy5.5) because the plateau of tumor fluorescence was reached by 4 hours postinjection and accumulation was not maximal at the initial 2-hour time point. In mice, plasma half-lives range from 47 minutes for a tat -CLIO conjugate to 650 minutes for the nonpeptideconjugated parent CLIO nanoparticle [25] . It appears that the uptake of ESBP-CLIO(Cy5.5) is mediated by E-selectin in vitro and in vivo.
LLC tumors were then submitted for histology to determine the cells accumulating ESBP-CLIO(Cy5.5), as shown in Figure 4 . Two representative sections of the tumors are shown with a different series of stains: one set where E-selectin is visualized (Figure 4 , A-D) and a second set where CD31, an endothelial cell marker, is visualized (Figure 4, E -H ) . ESBP-CLIO(Cy5.5) is visualized as Cy5.5 fluorescence, as shown in Figure 4 , A and E. To demonstrate the expected association of ESBP -CLIO(Cy5.5) uptake with E-selectin expression on endothelial cells, we stained sections with anti-CD31 ( Figure 4F ). However, we found that ESBP -CLIO(Cy5.5) was associated with both strongly CD31-positive cells and non -CD31-staining cells. A composite of Figure 4 , A and B is shown in Figure 4D , together with an additional nuclear stain ( Figure 4C ). It thus appeared that ESBP -CLIO(Cy5.5) was not only associated with endothelial cells but was present on tumor cells as well. To further verify this point, a second tumor section was obtained and stained with anti -E-selectin ( Figure 4B ). Both ESBP -CLIO(Cy5.5) and E-selectin were widely distributed throughout the tumor and were not associated with any specific cells. A composite of Figure 4 , E and F is shown in Figure 4H , together with an additional nuclear stain ( Figure 4G ). Although in vitro experiments with HUVECs Figure 6 . E-selectin expression in the human prostate. Representative images of specimens rated as high positive, medium positive, low positive, or negative for E-selectin expression by immunohistochemistry are shown. Also shown are the numbers of specimens in each category. Samples were from prostates with histologically confirmed adenocarcinomas. 
indicated that ESBP-CLIO(Cy5.5) was internalized in IL-1b -activated cells by an interaction with E-selectin, it appeared that E-selectin expression and accumulation of ESBP -CLIO (Cy5.5) occurred throughout the tumor. We next examined whether E-selectin might be expressed on LLC cells grown in vitro. Figure 5A shows the uptake of ESBP -CLIO(Cy5.5) and Scram -CLIO(Cy3.5) by LLC using a single-channel flow cytometry analysis. With ESBP -CLIO(Cy5.5), both high-and low-binding populations of cells were clearly discernable, whereas with the Scram -CLIO(Cy3.5) nanoparticle, only a single low-binding population was obtained. The accumulation of ESBP -CLIO(Cy5.5) was further examined by the dual-wavelength flow cytometry using PE-labeled anti -E-selectin, as shown in Figure 5B . As was the case with the single-channel flow cytometry ( Figure 5A ), a population of cells labeled with both ESBP -CLIO(Cy5.5) and anti-E-selectin was present (26.9% of cells). However, this population appeared to have less ESBP -CLIO(Cy5.5) uptake or E-selectin expression than HUVECs (compare Figure 5 , B and C). Thus, it appears that E-selectin is expressed by LLCs both in vivo and in vitro, but this expression is at a lower level than that seen when IL-1b induces E-selectin expression on HUVECs. The treatment of LCC with IL-1b had no effect on the binding of ESBP -CLIO(Cy5.5) to LLC (data not shown).
The expression of E-selectin on endothelial cells was well established, but we were unaware of reports of its expression on tumor cells until the recent report [26] . We therefore obtained an array of 72 human prostate specimens from prostates with histologically confirmed adenocarcinomas. Of these, 67 could be evaluated for E-selectin expression by immunohistochemistry. Samples were rated as high positive, medium positive, low positive, and negative, representative specimens of which are shown in Figure 6A . As shown in Figure 6B , 38 of 67 samples evaluated were rated as strongly positive for E-selectin expression.
Discussion

Specificity
A key issue for molecularly targeted optical nanoparticles is the specificity of their molecular targeting in vivo. Determining molecular specificity in vivo with peptide -nanoparticle conjugates (10-200 nm) using a peptide to block interactions between a peptide-nanoparticle conjugate and its target is difficult because of limitations of peptide solubility; in addition, the plasma half-life of peptides is often far shorter than the half-life of nanoparticles whose binding they are proposed to inhibit. The problem of demonstrating nanoparticle specificity in vivo is exacerbated by the ability of nonmolecularly targeted magnetic nanoparticles to accumulate in diverse types of pathology. Although magnetic nanoparticles accumulate in the normal liver, spleen, and lymph nodes [27 -31] , their accumulation in a variety of pathologies also occurs. Nontargeted nanoparticle accumulation occurs at the sites of infection [32, 33] , in atherosclerotic vessels [34 -36] , and in rheumatoid arthritis [37] . Nanoparticle accumulation has also been seen in several types of tumors, such as those of the brain [38, 39] and head and neck [40] . To minimize the possibility of non -E-selectin -mediated uptake contributing to tissue fluorescence, we used 3 mg Fe/kg ESBP -CLIO(Cy5.5), which was only slightly higher than the clinical dose of 2.6 mg/kg Fe [31] . To determine the molecular specificity of ESBP -CLIO(Cy5.5) in vivo, the nanoparticle and Scram -CLIO(Cy3.5) were coinjected and fluorescence reflectance images were obtained using dual-channel fluorescent imaging methods [22] . The progressive increase in the Cy5.5/Cy3.5 ratio in the LLC with time provided evidence of the E-selectin -mediated accumulation of ESBP -CLIO(Cy5.5) in vivo.
Sensitivity, Uptake, and the Presence of E-selectin on Tumor Cells
It appears that the fluorescence of ESBP -CLIO(Cy5.5) nanoparticles, when used in conjunction with near-infrared fluorescent imaging, has the sensitivity to detect low levels of E-selectin expression in the LLC. The explanation for this high sensitivity lies in the rapid E-selectin -mediated internalization of ESBP -CLIO(Cy5.5), even at low concentrations. In addition, the binding of ESBP -CLIO(Cy5.5) triggers endocytosis and intracellular accumulation (Figure 2A) , with negligible nanoparticle loss in the 24-hour period of our longest experiments [18, 39] . Finally, when E-selectin-binding ligands are internalized, plasma membrane E-selectin is rapidly replaced [41] .
Expression on Human Cells
We found that ESBP -CLIO(Cy5.5) binding and E-selectin expression were not limited to endothelial cells in the LLC both in vivo (Figure 4 ) and in vitro ( Figure 5 ). Bhaskar et al. [26] have recently reported that E-selectin mRNA and immunoreactive E-selectin were overexpressed in human prostate cancer specimens even though E-selectin expression was not detected in human cancer cell lines of prostatic origin, normal human tissues, or nonprostatic cancers. We have confirmed the expression of E-selectin in the human prostate cancer epithelium using immunohistochemistry ( Figure 6 ). Our results indicate that E-selectin expression in the LLC model, a tumor of murine origin, can be imaged by optical methods and that E-selectin expression can be detected by immunohistochemistry in human prostate cancer specimens. The lack of expression of Eselectin on cultured human cell lines and xenographs [26] , however, means that there is currently no model suitable for imaging E-selectin expression with cancers of human origin. The lack of expression of E-selectin on human prostate cancer cell lines and its expression in human prostatic cancers suggest that unknown tissue-based environmental factors cause its upregulation or downregulation [26] and complicate efforts to study E-selectin function in vitro. Thus, the comparison of E-selectin expression on LLC and endothelial cells ( Figure 5 ) may be between cells expressing basal levels of E-selectin (LLC) and those where it is highly upregulated (IL-1b/endothelial cells). Further determinations of which tumor cells express E-selectin, its function, and the regulation of its expression are questions of considerable interest.
